Dr. Maged Aljahel


Consultant Of Internal medicine and Medical Oncology in King Salman bin Abdulaziz Medical city - Madinah
Associate Executive Director of Oncology & Hematology Center in King Salman bin Abdulaziz Medical city - Madinah
Vice President of the Saudi Oncology Society SOS

09:45 –10:30

Friday 3-5-2024 Day 1

Role of anthracyclines in early breast cancer

  • When to omit anthracyclines in(neo) adjuvant therapy of HER2-negative breast cancer

    When to use anthracyclines in (neo) adjuvant therapy of HER2-positive breast cancer

Moderator:Dr. Meteeb Alfohaidi



Friday 3-5-2024 Day 1

Transition from hormonal-based to chemotherapy in metastatic BC??

  • Patients with early progression on CDK4-6 inhibitors: What is next??
  • When to start ADCs/olaparib in patients who had visceral crisis?? Can be upfront??
  • Any role of hormonal monotherapy after CDK4-6 inhibitors??
  • Biomarkers to guide subsequent therapies
  • Can we use one ADC after previous ADC??

Moderator:  Dr. Ahmed Alfaraj